Integrating a Tumor Size‐Overall Survival Model Into a Spatial Quantitative Systems Pharmacology Framework for Antibody‐Drug Conjugates in Non‐Small Cell Lung Cancer
Open Access
- 9 October 2026
- journal article
- research article
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 15 (10) , e70352
Abstract
Antibody‐drug conjugate (ADC) development in solid tumors faces efficacy and safety challenges from heterogeneous target expression, limited tumor penetration, and off‐target payload exposure. We developed a spatial quantitative systems pharmacology (QSP) framework integrating ADC‐analyte physiologically based pharmacokinetics (PBPK), a Krogh‐cylinder tumor model, and a non‐small cell lung cancer (NSCLC) tumor size‐overall survival (TS‐OS) relationship developed without ADC‐treated populations. Applied to trastuzumab deruxtecan (T‐DXd) in HER2‐mutant NSCLC and datopotamab deruxtecan (Dato‐DXd), a TROP2‐directed ADC, in EGFR‐mutated NSCLC, all parameters came from literature or independent assays; only nonspecific antibody uptake and unconjugated‐payload hepatic clearances were estimated from population‐level T‐DXd serum PK. Using a common structure and virtual‐patient framework with independently informed ADC‐specific inputs, simulations generated PK, objective response rate (ORR), disease control rate (DCR), and exploratory OS trends consistent with clinical data. Heterogeneous tumor trajectories emerged without fitting individual trajectories, adding ad hoc response compartments, or retuning tumor growth solely to reproduce ORR/DCR. Tumor growth kinetics and target‐expression characteristics, represented by histological score and antigen‐positive cell fraction, were associated with response, but responder/non‐responder distributions overlapped, indicating limited discrimination and need for predictive biomarkers. The TS‐OS sub‐model reproduced median OS and survival trends, supporting transportability despite absent individual‐level tumor and survival data. Tumor growth rate was the strongest survival‐associated input, consistent with TS‐OS covariate structure. Across doses, 5.4 mg/kg Q3W T‐DXd and 6 mg/kg Q3W Dato‐DXd were preferred based on predicted efficacy and off‐tumor tissue payload exposure, consistent with approved doses. The framework supports ADC design and dose evaluation despite limited individual‐level data.Keywords
Funding Information
- GlaxoSmithKline
This publication has 46 references indexed in Scilit:
- A QSP PDE model of ADC transport and kinetics in a growing or shrinking tumorJournal of Pharmacokinetics and Pharmacodynamics, 2025
- Towards a platform quantitative systems pharmacology (QSP) model for preclinical to clinical translation of antibody drug conjugates (ADCs)Journal of Pharmacokinetics and Pharmacodynamics, 2023
- Development of a Physiologically-Based Pharmacokinetic Model for Whole-Body Disposition of MMAE Containing Antibody-Drug Conjugate in MicePharmaceutical Research, 2022
- Antibody Conjugation of a Chimeric BET Degrader Enables in vivo ActivityChemMedChem, 2019
- Establishing in vitro–in vivo correlation for antibody drug conjugate efficacy: a PK/PD modeling approachJournal of Pharmacokinetics and Pharmacodynamics, 2018
- Quantitative characterization of in vitro bystander effect of antibody-drug conjugatesJournal of Pharmacokinetics and Pharmacodynamics, 2016
- On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approachJournal of Pharmacokinetics and Pharmacodynamics, 2013
- Applications of minimal physiologically-based pharmacokinetic modelsJournal of Pharmacokinetics and Pharmacodynamics, 2012
- Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotinJournal of Pharmacokinetics and Pharmacodynamics, 2012
- Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and humanJournal of Pharmacokinetics and Pharmacodynamics, 2011